ccr5 receptors

Summary

Summary: Seven-transmembrane G protein-coupled receptors for beta-chemokines. They also function as fusion cofactors for macrophage-tropic HIV-1 strains.

Top Publications

  1. pmc Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
    Jeannette M Whitcomb
    Monogram Biosciences, Inc, 345 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Antimicrob Agents Chemother 51:566-75. 2007
  2. ncbi Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
    P D Kwong
    Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, USA
    Nature 393:648-59. 1998
  3. pmc CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Dr, Room 3509, Bethesda, MD 20892, USA
    J Exp Med 200:749-59. 2004
  4. ncbi Identification of a major co-receptor for primary isolates of HIV-1
    H Deng
    Skirball Institute for Biomolecular Medicine, New York University Medical Center, 10016, USA
    Nature 381:661-6. 1996
  5. pmc Structure of a V3-containing HIV-1 gp120 core
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Science 310:1025-8. 2005
  6. ncbi HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
    T Dragic
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York 10016, USA
    Nature 381:667-73. 1996
  7. ncbi The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
    H Choe
    Division of Human Retrovirology Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cell 85:1135-48. 1996
  8. pmc Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences
    Mark A Jensen
    Department of Microbiology, University of Washington, Seattle, Washington 98195 8070, USA
    J Virol 77:13376-88. 2003
  9. ncbi DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
    T B Geijtenbeek
    Department of Tumor Immunology, University Medical Center St Radboud, Nijmegen, The Netherlands
    Cell 100:587-97. 2000
  10. pmc Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice
    L Boring
    Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141 9100, USA
    J Clin Invest 100:2552-61. 1997

Detail Information

Publications317 found, 100 shown here

  1. pmc Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
    Jeannette M Whitcomb
    Monogram Biosciences, Inc, 345 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Antimicrob Agents Chemother 51:566-75. 2007
    ....
  2. ncbi Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
    P D Kwong
    Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, USA
    Nature 393:648-59. 1998
    ..Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to intervene...
  3. pmc CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Dr, Room 3509, Bethesda, MD 20892, USA
    J Exp Med 200:749-59. 2004
    ....
  4. ncbi Identification of a major co-receptor for primary isolates of HIV-1
    H Deng
    Skirball Institute for Biomolecular Medicine, New York University Medical Center, 10016, USA
    Nature 381:661-6. 1996
    ..The principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR-5, a receptor for the beta-chemokines RANTES, MIP-1alpha and MIP-1beta...
  5. pmc Structure of a V3-containing HIV-1 gp120 core
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Science 310:1025-8. 2005
    ..The extended nature and antibody accessibility of V3 explain its immunodominance. Together, the results provide a structural rationale for the role of V3 in HIV entry and neutralization...
  6. ncbi HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
    T Dragic
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York 10016, USA
    Nature 381:667-73. 1996
    ..CC-CKR-5 is a second receptor for NSI primary viruses...
  7. ncbi The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
    H Choe
    Division of Human Retrovirology Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cell 85:1135-48. 1996
    ..The ability of various members of the chemokine receptor family to support the early stages of HIV-1 infection helps to explain viral tropism and beta-chemokine inhibition of primary HIV-1 isolates...
  8. pmc Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences
    Mark A Jensen
    Department of Microbiology, University of Washington, Seattle, Washington 98195 8070, USA
    J Virol 77:13376-88. 2003
    ..We found that X4 viruses were lost in two ways: by the dying off of an established X4 lineage or by mutation back to low-scoring V3 loops...
  9. ncbi DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
    T B Geijtenbeek
    Department of Tumor Immunology, University Medical Center St Radboud, Nijmegen, The Netherlands
    Cell 100:587-97. 2000
    ..We propose that DC-SIGN efficiently captures HIV-1 in the periphery and facilitates its transport to secondary lymphoid organs rich in T cells, to enhance infection in trans of these target cells...
  10. pmc Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice
    L Boring
    Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141 9100, USA
    J Clin Invest 100:2552-61. 1997
    ..These data suggest an important and unexpected role for CCR2 activation in modulating the immune response, as well as in recruiting monocytes/macrophages to sites of inflammation...
  11. ncbi Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved?
    Leonid Margolis
    National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20895, USA
    Nat Rev Microbiol 4:312-7. 2006
    ..Here, we propose that there is no single gatekeeper and that, instead, the selective transmission of R5 HIV-1 depends on the superimposition of multiple imperfect gatekeepers...
  12. pmc Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4
    Chih Chin Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 317:1930-4. 2007
    ....
  13. pmc Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage
    A Mörner
    Microbiology and Tumorbiology Center MTC, Karolinska Institute, Swedish Institute for Infectious Disease Control, Stockholm, Sweden
    J Virol 73:2343-9. 1999
    ..The results indicate no obvious link between viral virulence and the ability to use a multitude of coreceptors...
  14. ncbi Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection
    Joseph J Mattapallil
    Immunotechnology Section, Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA
    Nature 434:1093-7. 2005
    ..Our findings point to the importance of reducing the cell-associated viral load during acute infection through therapeutic or vaccination strategies...
  15. ncbi Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
    R Liu
    Aaron Diamond AIDS Research Center, Rockefeller University New York, New York 10016, USA
    Cell 86:367-77. 1996
    ..These findings indicate the importance of CKR-5 in HIV-1 transmission and suggest that targeting the HIV-1-CKR-5 interaction may provide a means of preventing or slowing disease progression...
  16. pmc Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection
    William G Glass
    Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 202:1087-98. 2005
    ..We conclude that CCR5 is a critical antiviral and survival determinant in WNV infection of mice that acts by regulating trafficking of leukocytes to the infected brain...
  17. ncbi CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia
    J He
    Division of Human Retrovirology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 385:645-9. 1997
    ..The CCR3 ligand, eotaxin, and an anti-CCR3 antibody inhibited HIV-1 infection of microglia, as did MIP-1beta, which is a CCR5 ligand. Our results suggest that both CCR3 and CCR5 promote efficient infection of the CNS by HIV-1...
  18. pmc Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations
    C Pastore
    The Scripps Research Institute, Dept of Immunology, La Jolla, CA 92037, USA
    J Virol 80:750-8. 2006
    ..HIV-1 envelope sequence evolution from CCR5 to CXCR4 use is constrained by relatively frequent lethal mutations, deep fitness valleys, and requirements to make the right amino acid substitution in the right place at the right time...
  19. pmc The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor
    Emmanuel G Cormier
    Microbiology and Immunology Department, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Virol 76:8953-7. 2002
    ..Our data support a two-site gp120-CCR5 binding model wherein the V3 crown and stem interact with distinct regions of CCR5 in order to mediate viral entry...
  20. pmc Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
    Jesus F Salazar-Gonzalez
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 206:1273-89. 2009
    ..These findings reveal viral properties associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive mutations driven primarily, but not exclusively, by early cytotoxic T cell responses...
  21. pmc A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5
    M Farzan
    Dana Farber Cancer Institute, Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA
    J Virol 72:1160-4. 1998
    ..These results identify a region of CCR5 that is necessary for the physical association of the gp120 envelope glycoprotein with CCR5 and for HIV-1 infection...
  22. ncbi The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility
    Enrique Gonzalez
    Veterans Administration Research Center for AIDS and HIV 1 Infection, South Texas Veterans Health Care System, and Department of Medicine, University of Texas Health Science Center, San Antonio, TX 78229, USA
    Science 307:1434-40. 2005
    ....
  23. ncbi Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
    Gerd Fatkenheuer
    Department of Internal Medicine, Division of Infectious Diseases, Haus 11, University of Cologne, Joseph Stelzmann Strasse 9, D 50924 Cologne, Germany
    Nat Med 11:1170-2. 2005
    ..6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach...
  24. ncbi Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry
    M Farzan
    Dana Farber Cancer Institute, Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cell 96:667-76. 1999
    ..CXCR4, another important HIV-1 coreceptor, is also sulfated. Tyrosine sulfation may contribute to the natural function of many 7TMS receptors and may be a modification common to primate immunodeficiency virus coreceptors...
  25. pmc Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
    Mike Westby
    Globel Research and Development, Pfizer Ltd, Sandwich Labs, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom
    J Virol 81:2359-71. 2007
    ..This hypothesis was further corroborated by the observation that a high concentration of maraviroc blocks the activity of aplaviroc against maraviroc-resistant virus...
  26. pmc R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells
    Claudia Cicala
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:3746-51. 2006
    ..Additionally, signaling by R5 gp120 may facilitate the transmission of R5 viruses by inducing a permissive environment for HIV replication...
  27. ncbi The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection
    John P Moore
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
    AIDS Res Hum Retroviruses 20:111-26. 2004
    ..We will also review what might happen when coreceptor antagonists are used clinically to treat HIV-1 infection...
  28. pmc A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection
    M A Poles
    Department of Medicine, UCLA School of Medicine, UCLA Center for HIV and Digestive Diseases, Los Angeles, California 90095, USA
    J Virol 75:8390-9. 2001
    ..We conclude that, based on these findings, the gastrointestinal mucosa represents a favored target for HIV-1, in part due to its large population of CXCR4(+) CCR5(+) target cells and not to differences in the virus that it contains...
  29. pmc Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5
    C B Davis
    Division of Molecular Pathogenesis, Skirball Institute for Biomolecular Medicine, NYU Medical Center 10016, USA
    J Exp Med 186:1793-8. 1997
    ..The results presented here provide the first evidence for activation of an intracellular signaling event that can initiate multiple signaling pathways as a consequence of contact between HIV-1 and chemokine receptors...
  30. ncbi Recruitment of HIV and its receptors to dendritic cell-T cell junctions
    David McDonald
    Department of Microbiology and Immunology, University of Illinois, Chicago, IL 60612, USA
    Science 300:1295-7. 2003
    ..We propose that contact between dendritic cells and T cells facilitates transmission of HIV by locally concentrating virus, receptor, and coreceptor during the formation of an infectious synapse...
  31. ncbi Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic
    Jean K Lim
    Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Infect Dis 197:262-5. 2008
    ..1 [95% CI, 0.9-11.2] [P= .06]). A meta-analysis of all 4 cohorts showed an OR of 4.2 (95% CI, 2.1-8.3 [P= .0001]). Thus, CCR5 deficiency is a strong and consistent risk factor for symptomatic WNV infection in the United States...
  32. ncbi The HIV coreceptor switch: a population dynamical perspective
    Roland R Regoes
    Department of Biology, Emory University, 1510 Clifton Rd NE, Atlanta, Georgia 30322, USA
    Trends Microbiol 13:269-77. 2005
    ....
  33. ncbi Chemokines as regulators of T cell differentiation
    S A Luther
    Howard Hughes Medical Institute and Department of Microbiology and Immunology, University of California San Francisco, 513 Parnassus Ave, San Francisco, CA 94143 0414, USA
    Nat Immunol 2:102-7. 2001
    ..Models to account for the action of chemokines and G protein-coupled receptor signals in regulating T cell differentiation are discussed...
  34. ncbi CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells
    J Aliberti
    Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Nat Immunol 1:83-7. 2000
    ..These findings support the concept that the early induction of chemokines by invading pathogens is a critical step not only for the recruitment of DC but also for the determination of their subsequent immunologic function...
  35. pmc Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
    Shawn E Kuhmann
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Virol 78:2790-807. 2004
    ..2-CCR5 cells under conditions where gp120 proteins from the parental virus and a partially AD101-resistant virus bound strongly. Hence, the full impact of the V3 substitutions may only be apparent at the level of the native Env complex...
  36. ncbi Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease
    E A Berger
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Immunol 17:657-700. 1999
    ..Beyond providing new perspectives on fundamental aspects of HIV-1 transmission and pathogenesis, the coreceptors suggest new avenues for developing novel therapeutic and preventative strategies to combat the AIDS epidemic...
  37. pmc Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
    Mike Westby
    Pfizer Global Research and Development, Sandwich, United Kingdom
    J Virol 80:4909-20. 2006
    ..Importantly, in all three patients, circulating virus reverted to predominantly CCR5 tropic following cessation of maraviroc...
  38. pmc Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
    Jasminka Sterjovski
    Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
    Retrovirology 4:89. 2007
    ....
  39. pmc Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells
    A Granelli-Piperno
    Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021, USA
    J Virol 72:2733-7. 1998
    ..Therefore, the developmental stage of DCs can influence the interaction of these cells with HIV-1 and influence the extent to which M-tropic and T-tropic virus can replicate...
  40. pmc Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics
    Kara G Lassen
    Department of Molecular Biology and Microbiology, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
    PLoS Pathog 5:e1000377. 2009
    ..These results imply that lower env fitness may be established early and may directly contribute to viral suppression in ES individuals...
  41. pmc Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Fl, New York, NY 10016, USA
    J Exp Med 200:761-70. 2004
    ..Given the importance of the mucosal compartment in HIV-1 pathogenesis, further study to elucidate the significance of the changes observed here is critical...
  42. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  43. pmc Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein
    Shi Hua Xiang
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute and Harvard Medical School Boston, Massachusetts 02115, USA
    J Virol 76:9888-99. 2002
    ..These results indicate that CD4BS antibodies recognize conformations of gp120 different from that recognized by CD4 and CD4i antibodies...
  44. pmc Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines
    Bruce K Brown
    The Henry M Jackson Foundation, 13 Taft Court, Suite 200, Rockville, MD 20850, USA
    J Virol 79:6089-101. 2005
    ....
  45. pmc Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41
    Cleo G Anastassopoulou
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 106:5318-23. 2009
    ..Together, the experimental results and theoretical model may help understand how HIV-1 uses CCR5 to enter target cells under various conditions...
  46. pmc In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, USA
    J Virol 82:8210-4. 2008
    ..Pretreatment V3 loop sequences reemerged following VCV discontinuation, implying that VCV resistance has associated fitness costs...
  47. ncbi CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist
    C Blanpain
    IRIBHN and Service de Génétique Médicale, Universite Libre de Bruxelles, Campus Erasme, Bruxelles, Belgium
    Blood 94:1899-905. 1999
    ..MCP-3 could compete efficiently for gp120 binding but was, however, found to be a weak inhibitor of HIV infection, probably as a consequence of its inability to downregulate the receptor...
  48. ncbi The cerebral-malaria-associated expression of RANTES, CCR3 and CCR5 in post-mortem tissue samples
    B Y Sarfo
    Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310 1495, USA
    Ann Trop Med Parasitol 98:297-303. 2004
  49. ncbi Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells
    Julio Aliberti
    Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Nat Immunol 4:485-90. 2003
    ..The ability to generate this strong protective response may benefit parasite transmission by preventing the protozoan from overwhelming its intermediate hosts...
  50. pmc The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages
    S Aquaro
    Laboratory of Experimental Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    J Virol 75:4402-6. 2001
    ..LD78beta strongly downregulated CCR5 expression in M/M, thereby explaining its potent antiviral activity...
  51. ncbi Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease
    Arantxa Apolinario
    Hepatology Unit, University Hospital Santa Cristina, Madrid, Spain
    Am J Gastroenterol 97:2861-70. 2002
    ..Although chemokines seem to be important in certain inflammatory disorders, little is known about the role of these proteins in chronic hepatitis C...
  52. ncbi HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    AIDS 21:693-702. 2007
    ..An effective HIV-1 vaccine or microbicide must block the transmitted virus variants that initially establish a new infection; consequently, it is critical that such viruses be isolated and characterized...
  53. pmc Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5
    Xiao Feng Qin
    Division of Biology, California Institute of Technology, Pasadena 91125, USA
    Proc Natl Acad Sci U S A 100:183-8. 2003
    ..Thus, our studies demonstrate the feasibility and potential of lentiviral vector-mediated delivery of siRNAs as a general means of intracellular immunization for the treatment of HIV-1 and other viral diseases...
  54. ncbi Use of chemokine receptors by poxviruses
    A S Lalani
    The John P Robarts Research Institute and Department of Immunology, The University of Western Ontario, London, Ontario N6G 2V4, Canada
    Science 286:1968-71. 1999
    ..These findings suggest that poxviruses, like HIV, are able to use chemokine receptors to infect specific cell subtypes, notably migratory leukocytes, but that their mechanisms of receptor interactions are distinct...
  55. ncbi Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library
    Keisuke Yusa
    Department of Medical Virology, Graduate School of Medical Sciences, Kumamoto University, 2 1 1 Honjo, Kumamoto 860 8556, Japan
    J Biol Chem 280:30083-90. 2005
    ..Taken together, this type of HIV-1 V3 loop library is useful for isolating and analyzing the specific biological features of HIV-1 with respect to alterations of the V3 loop structure...
  56. ncbi Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists
    Rama Kondru
    Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304, USA
    Mol Pharmacol 73:789-800. 2008
    ..The fully mapped binding pocket of CCR5 is being used for structure-based design and lead optimization of novel anti-HIV CCR5 inhibitors with improved potency and better resistance profile...
  57. pmc Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient
    Evelien M Bunnik
    Department of Clinical Viro Immunology, Sanquin Research and Landsteiner Laboratory at the Academic Medical Center, University of Amsterdam and Center for Infection and Immunity Amsterdam CINIMA, Amsterdam, The Netherlands
    J Virol 81:525-31. 2007
    ....
  58. ncbi Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesis
    Josianne Nitcheu
    Institut National de la Sante et de la Recherche Medicale, Unité 511, Immunobiologie Cellulaire et Moleculaire des Infections Parasitaires, CHU Pitie Salpetriere, Universite Pierre et Marie Curie, 91 Boulevard de l Hopital, 75634 Paris Cedex 13, France
    J Immunol 170:2221-8. 2003
    ..Thus, lymphocyte cytotoxicity and cell trafficking are key players in ECM pathogenesis...
  59. ncbi The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4
    Pavel Pugach
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Virology 321:8-22. 2004
    ..The loss of neutralization resistance is of no relevance under in vitro conditions, but NAbs would presumably be a counter-selection pressure against such adaptive changes in vivo, at least when the humoral immune response is intact...
  60. ncbi Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver
    P L Shields
    Liver Research Laboratories and Department of Rheumatology, Medical Research Council Centre for Immune Regulation, University of Birmingham, Birmingham, United Kingdom
    J Immunol 163:6236-43. 1999
    ....
  61. ncbi Chemokine receptor CCR5: insights into structure, function, and regulation
    Martin Oppermann
    Department of Immunology, Georg August University Gottingen, Kreuzbergring 57, 37075, Germany
    Cell Signal 16:1201-10. 2004
    ..This review discusses recent advances in the elucidation of the structure and function of CCR5, as well as the complex mechanisms that regulate CCR5 signalling and cell surface expression...
  62. pmc The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source
    C Goulding
    Department of Clinical Medicine and Dublin Molecular Medicine Centre, Trinity Centre for Health Sciences, St James Hospital, Ireland
    Gut 54:1157-61. 2005
    ..The aim of this study was to assess the involvement of inherited variations in CCR2, CCR5, and the ligand RANTES in determining disease outcome in hepatitis C virus (HCV) infected individuals...
  63. pmc Characterization of novel simian immunodeficiency viruses from red-capped mangabeys from Nigeria (SIVrcmNG409 and -NG411)
    B E Beer
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 20852, USA
    J Virol 75:12014-27. 2001
    ..SIVrcm, SIVsm, SIVmndGB1, and all four SIVlhoest isolates but not SIVsun (from sun-tailed monkeys) replicated efficiently in human PBMC, suggesting that the ability to infect the human host can vary within one lineage...
  64. pmc Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120
    E G Cormier
    Albert Einstein College of Medicine, Microbiology and Immunology Department, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Proc Natl Acad Sci U S A 97:5762-7. 2000
    ..More importantly, the Nt domain determines the specificity of the interaction between CCR5 and gp120s from isolates that use this coreceptor...
  65. pmc A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains
    Samantha H Johnston
    Division of Pediatric Infectious Diseases, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    J Virol 83:11016-26. 2009
    ..Our affinity-profiling system may help to refine studies of R5 virus tropism and pathogenesis...
  66. pmc The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions
    S Qin
    LeukoSite, Inc, Cambridge, Massachusetts 02142, USA
    J Clin Invest 101:746-54. 1998
    ..Moreover, CXCR3 and CCR5 appear to identify subsets of T cells in blood with a predilection for homing to these sites...
  67. ncbi Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha
    C J Raport
    ICOS Corporation, Bothell, Washington 98021, USA
    J Biol Chem 271:17161-6. 1996
    ..CCR5 is expressed in lymphoid organs such as thymus and spleen, as well as in peripheral blood leukocytes, including macrophages and T cells, and is the first example of a human chemokine receptor that signals in response to MIP-1beta...
  68. pmc Chemokine receptor homo- or heterodimerization activates distinct signaling pathways
    M Mellado
    Department of Immunology and Oncology, Centro Nacional de Biotecnologia CSIC, Universidad Autonoma de Madrid, Campus de Cantoblanco, E 28049 Madrid, Spain
    EMBO J 20:2497-507. 2001
    ..These results show the effect of heterodimer formation on increasing the sensitivity and dynamic range of the chemokine response, and may aid in understanding the dynamics of leukocytes at limiting chemokine concentrations in vivo...
  69. ncbi A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
    B J Doranz
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia 19104, USA
    Cell 85:1149-58. 1996
    ....
  70. pmc Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone
    B Renjifo
    Harvard AIDS Institute and Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Virol 75:4964-72. 2001
    ..The clone may also be used in experimental design of vaccine candidates that may be directed against HIV-1 subtype C...
  71. ncbi The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
    Christian Watson
    Assay Development and Compound Profiling, GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    Mol Pharmacol 67:1268-82. 2005
    ..This idea is discussed in terms of using these drugs sequentially to overcome HIV viral resistance in the clinic...
  72. pmc Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry
    Brooke Harmon
    Division of Molecular Oncology, Washington University School of Medicine, St Louis, Missouri, USA
    J Virol 82:9191-205. 2008
    ..These results could provide a new focus for therapeutic intervention with drugs targeting host signaling mediators rather than viral molecules, a strategy which is less likely to result in resistance...
  73. pmc Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions
    James M Binley
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:5678-84. 2003
    ..Overall, this disulfide-shackled virus is a unique tool with potential utility in vaccine design, drug discovery, and elucidation of the HIV-1 entry process...
  74. pmc Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains
    Paolo Lusso
    Unit of Human Virology, Department of Biological and Technological Research DIBIT, San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy
    J Virol 79:6957-68. 2005
    ....
  75. pmc Mobility of the human immunodeficiency virus (HIV) receptor CD4 and coreceptor CCR5 in living cells: implications for HIV fusion and entry events
    Carolyn M Steffens
    Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, Illinois, USA
    J Virol 78:9573-8. 2004
    ..Interestingly, our findings also suggest that the seven-span transmembrane coreceptor is significantly more mobile than CD4 and requires membrane cholesterol for mobility...
  76. ncbi Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice
    Niels R Veillard
    Division Cardiology, Foundation for Medical Research, University Hospital Geneva, Geneva, Switzerland
    Circ Res 94:253-61. 2004
    ..Thus, our findings indicate that blockade of chemokine receptor/ligand interactions might become a novel therapeutic strategy to reduce the evolution of this common disease...
  77. ncbi Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates
    Mia Coetzer
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Private Bag X4, Sandringham, Johannesburg, Gauteng 2131, South Africa
    Virology 356:95-105. 2006
    ..We therefore suggest that changes within the crown motif of subtype C viruses might be an additional pathway to utilise CXCR4 and thus GPGQ may limit the potential for the development of X4 viruses...
  78. ncbi Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells
    D Jarrossay
    Institute for Research in Biomedicine, Bellinzona, Switzerland
    Eur J Immunol 31:3388-93. 2001
    ..These results reveal a remarkable specialization and complementarity in microbial molecule recognition as well as a flexibility in effector function among myeloid and plasmacytoid DC...
  79. pmc Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes
    Eric J Kunkel
    Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
    Am J Pathol 160:347-55. 2002
    ....
  80. ncbi Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction
    Flora Castellino
    Lymphocyte Biology Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 440:890-5. 2006
    ....
  81. ncbi Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211
    Roy M Gulick
    Weill Medical College of Cornell University, New York, New York, NY, USA
    J Infect Dis 196:304-12. 2007
    ..Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study...
  82. ncbi Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES
    C Combadiere
    The Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Leukoc Biol 60:147-52. 1996
    ..These data suggest that CC CKR5 is a G(i)-coupled receptor that may mediate monocyte responses to MIP-1alpha, MIP-1beta, and RANTES...
  83. ncbi CCR5 mediates specific migration of Toxoplasma gondii-primed CD8 lymphocytes to inflammatory intestinal epithelial cells
    Souphalone Luangsay
    Department of Microbiology Immunology, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA
    Gastroenterology 125:491-500. 2003
    ..However, the mechanism responsible for the IEL migration to the inflamed intestine is still unclear...
  84. pmc Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice
    Stefan Baenziger
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 103:15951-6. 2006
    ....
  85. pmc Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1
    Aran F Labrijn
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:10557-65. 2003
    ..The results identify hurdles in using CD4i epitopes as targets for antibody-mediated neutralization in vaccine design but also indicate that the CD4i regions could be efficiently targeted by small molecule entry inhibitors...
  86. ncbi A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
    C D Rizzuto
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
    Science 280:1949-53. 1998
    ..This conserved element may be a useful target for pharmacologic or prophylactic intervention in human immunodeficiency virus (HIV) infections...
  87. ncbi HIV type 1 chemokine receptor usage in mother-to-child transmission
    F Salvatori
    Unit of Immunobiology of HIV, DIBIT, San Raffaele Scientific Institute, 20132 Milan, Italy
    AIDS Res Hum Retroviruses 17:925-35. 2001
    ....
  88. ncbi The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen
    Laura Waters
    St Stephens AIDS Trust, Department of Genitourinary HIV Medicine, Chelsea and Westminster Hospital, London, United Kingdom
    Clin Infect Dis 46:1617-23. 2008
    ..Viruses may be R5 tropic, X4 tropic, or dual/mixed (D/M) tropic. R5-tropic virus predominates at high CD4 cell counts, with the number of X4-tropic strains increasing as CD4 cell count decreases...
  89. pmc Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes
    E G Cormier
    Microbiology and Immunology Department, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Virol 75:5541-9. 2001
    ..Our data suggest that gp120 docking to CCR5 is a multistep process involving several independent regions of the envelope glycoprotein and the coreceptor...
  90. ncbi Expression of CCR5 is increased in human monocyte-derived macrophages and alveolar macrophages in the course of in vivo and in vitro Mycobacterium tuberculosis infection
    M Fraziano
    Department of Biology, University of Rome Tor Vergata, Rome, Italy
    AIDS Res Hum Retroviruses 15:869-74. 1999
    ..These results show that CCR5 expression is enhanced in the course of in vitro MTB infection and during active pulmonary tuberculosis...
  91. ncbi Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice
    N Sato
    South Texas Veterans Health Care System, Audie L Murphy Division, Department of Medicine, University of Texas Health Science Center, San Antonio 78229, USA
    J Immunol 163:5519-25. 1999
    ..donovani infection. Our data also suggest that there might be cross-talk between TCR and chemokine receptor signaling pathways...
  92. pmc A role for chemokine receptor transactivation in growth factor signaling
    E Mira
    Department of Immunology and Oncology, , Consejo Superior de Investigaciones Cientificias, , Spain
    EMBO Rep 2:151-6. 2001
    ..Our results suggest that this extracellular growth factor-chemokine network represents a general mechanism connecting tumorigenesis and inflammation...
  93. pmc Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus
    T C Dawson
    Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7525, USA
    Am J Pathol 156:1951-9. 2000
    ....
  94. ncbi Cholesterol is essential for macrophage inflammatory protein 1 beta binding and conformational integrity of CC chemokine receptor 5
    Dzung H Nguyen
    Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
    Blood 99:4298-306. 2002
    ..Together, these data demonstrate that cholesterol and lipid rafts are important for the maintenance of the CCR5 conformation and are necessary for both the binding and function of this chemokine receptor...
  95. ncbi A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis
    Elin Kindberg
    Division of Molecular Virology, Medical Faculty, University of Linkoping, Linkoping, Sweden
    J Infect Dis 197:266-9. 2008
    ..026) only among patients with TBE and a higher allele prevalence among patients with TBE compared with the other groups studied. CCR5Delta32 allele prevalence also increased with the clinical severity of disease...
  96. pmc Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1
    B J Doranz
    Department of Pathology, University of Pennsylvania, Philadelphia 19104, USA
    J Virol 71:6305-14. 1997
    ..Finally, we developed a novel monoclonal antibody to CCR5 to assist in future studies of CCR5 expression...
  97. ncbi CCR5 deficiency decreases susceptibility to experimental cerebral malaria
    Elodie Belnoue
    Departement d Immunologie, Institut Cochin, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Rene Descartes, Hopital Cochin, Paris, France
    Blood 101:4253-9. 2003
    ..Taken together, these results suggest that CCR5 is an important factor in the development of experimental CM...
  98. ncbi Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data
    J P Ioannidis
    Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece
    Ann Intern Med 135:782-95. 2001
    ..Studies relating certain chemokine and chemokine receptor gene alleles with the outcome of HIV-1 infection have yielded inconsistent results...
  99. ncbi Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors
    Wieslaw Kazmierski
    Department of Medicinal Chemistry, GlaxoSmithKline Research and Development, Five Moore Drive, Research Triangle Park, NC 27709 3398, USA
    Bioorg Med Chem 11:2663-76. 2003
    ..Recent progress in the discovery and development of CCR5 antagonists, SAR and clinical status are reviewed. Finally, modeling-based structure of CCR5 is discussed in the context of a small-molecule antagonism of the CCR5 receptor...
  100. pmc Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection
    Ronald S Veazey
    Joan and Sanford I Weill Medical College of Cornell University, Dept of Microbiology and Immunology, 1300 York Ave, W 805, New York, NY 10021, USA
    J Exp Med 198:1551-62. 2003
    ..These findings support the development of small molecule CCR5 inhibitors as antiviral therapies, and possibly as components of a topical microbicide to prevent HIV-1 sexual transmission...
  101. pmc IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses
    Yvonne M Mueller
    Department of Microbiology and Immunology, and Center for Immunology and Vaccine Science, Drexel University College of Medicine, Philadelphia, PA 19129, USA
    J Immunol 180:350-60. 2008
    ..Finally, IL-15-treated acutely SIV-infected primates may serve as a useful model to investigate the poorly understood mechanisms that control viral set point and disease progression in HIV infection...

Research Grants65

  1. HIV-1 gp120 Mediated Chemotaxis of Blood Cells
    Ramesh Ganju; Fiscal Year: 2005
    ..These studies should assist in the development of novel strategies to protect or augment immune integrity in people with HIV disease. ..
  2. Characterization of CCR5 Receptor N-terminal domain
    Krishna Rajarathnam; Fiscal Year: 2005
    ..Most importantly, receptor decoys designed on the basis of CCR5 N-domain structure should result in drugs for preventing/treating HIV-related diseases. ..
  3. Chemokine Decoy Receptor for Therapy of Autoimmune Arthritis
    Kanneganti Murthy; Fiscal Year: 2012
    ..We will test this agent in a clinically-relevant small animal model and determine the most effective dose, in anticipation of definitive large animal studies to confirm its efficacy and safety. ..
  4. Chronic Granulomatous Lung Inflammation Elicited by Carbon Nanotubes
    Mary Jane Thomassen; Fiscal Year: 2013
    ..In summary, this unique investigation of MWCNT-elicited granulomatous lung disease is well suited for student participation in an area with environmental impact on human disease. ..
  5. Chemokine Decoy Receptor: a novel therapy of IBD
    Kanneganti Murthy; Fiscal Year: 2012
    ..We are developing a novel drug that specifically blocks the inflammatory process in this condition. We will test this agent in a series of clinically-relevant animal models of autoimmune colitis. ..
  6. Inhibition of CCR1/CCR5 mediated angiogenesis and joint destruction by EGCG
    Salah Uddin Ahmed; Fiscal Year: 2010
    ..IL-12)-induced RANTES/CCL5 and MIP-11/CCL3 ) production in RA synovial fibroblasts that are mediated via CCR1/CCR5 receptors. EGCG also inhibited IL-12-induced markers of cartilage and bone destruction (IL-6, VEGF, and PGE2), and ..
  7. The role of CCR5 in HIV-1 Tat and morphine-mediated neurodegeneration.
    Elizabeth M Podhaizer; Fiscal Year: 2013
    ..abstract_text> ..
  8. New tools to study leukocyte infiltration into the CNS
    CHARLES LEE HOWE; Fiscal Year: 2013
    ..depend upon signaling through the CXCR2 and CXCR3 axis, while monocyte trafficking may depend upon CCR2 and CCR5 receptors. Based on this concept, and in an effort to dissect the role of specific chemokine receptors in the ..
  9. Single-particle Reconstruction of HIV-1 Envelope Glycoprotein Trimers
    Joseph G Sodroski; Fiscal Year: 2013
    ..The unliganded HIV-1 Env glycoprotein complex exists in a high-energy state;upon binding to the CD4 and CCR5 receptors, the HIV-1 Env glycoproteins assume lower-energy conformations...
  10. Molecular and Cellular Determinants of Immunity to Histoplasmosis
    George S Deepe; Fiscal Year: 2013
    ..Our findings will contribute to a greater understanding of how the host can successfully defend against histoplasmosis. ..
  11. HIV-1 Preintegration Trafficking and Nuclear Localization
    ALAN N ENGELMAN; Fiscal Year: 2013
    ....
  12. Chemokines in healing myocardial infarction
    Nikolaos G Frangogiannis; Fiscal Year: 2013
    ..The findings may identify novel therapeutic targets for pharmacologic interventions and cell therapy in patients with acute myocardial infarction. ..
  13. Structure, Dynamics and Activation Mechanisms of Chemokine Receptors
    Tracy M Handel; Fiscal Year: 2013
    ..All of these studies will be augmented with computational modeling methods in order to rationally guide the experimental construct design and to interpret the biophysical data in a 3D context. ..
  14. Engineering Nanoscale Aptamer-based Biomaterials that Target Cellular Receptors
    Ravi S Kane; Fiscal Year: 2013
    ..use polyvalency to develop and characterize potent heterodivalent and polyvalent microbicides that bind to CCR5 receptors and prevent infection by a model pathogen, HIV...
  15. Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection
    Hans Peter Kiem; Fiscal Year: 2013
    ..Given our leading roles in Transplantation and HIV research, we believe we are uniquely positioned to move these concepts from a highly relevant nonhuman primate HIV/SHIV model toward a cure for HIV-infected patients. ..
  16. Long-acting, self-administered HIV therapy with th CCR5 antibody PRO 140
    Jeffrey M Jacobson; Fiscal Year: 2013
    ..Success would represent a major advance towards the introduction of long-acting HIV therapies as a complement to the current paradigm of daily lifetime adherence to treatment...
  17. Natural IgM antilymphocyte autoantibodies inhibit HIV-1
    PETER LOBO; Fiscal Year: 2003
    ..receptor was realized with epidemiological data clearly demonstrating that individuals expressing mutant CCR5 receptors had a slower progression of their HIV-1 infection...
  18. Chemokine receptor CCR5 antagonists as novel anti-HIV agents
    Yan Zhang; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  19. DNA & SOLUBLE MULTIMERIC IMMUNOGEN FOR HUMMORAL IMMUNITY
    Jon Oscherwitz; Fiscal Year: 1999
    ....
  20. Rapamycin Enhanced Efficiency of Anti-HIV Antibodies
    Antony Dimitrov; Fiscal Year: 2007
    ..The objective of this Phase I SBIR proposal is to identify potential combinations of rapamycin and antiviral antibodies that may have clinical potential. [unreadable] [unreadable] [unreadable]..
  21. Mucosal SIV-CCR5 receptor vaccine in SIV infection
    Thomas Lehner; Fiscal Year: 2004
    ..This novel immunization strategy, designed to generate innate and adaptive immunity, and targeting both the virus and its primary coreceptors may prove an effective approach in preventing or controlling HIV infection. ..
  22. Chemokines and Macrophages in HIV Neuronal Apoptosis
    Stuart Lipton; Fiscal Year: 2003
    ..knock out" mice in the presence and absence of wild-type microglia and astrocytes containing CXCR4 and CCR5 receptors. Alternatively, wild-type neurons will be incubated with microglia (or astrocytes) isolated from mice lacking ..
  23. MECHANISM OF REGULATION OF HIV-1 INFECTION BY CHEMOKINES
    Helena Schmidtmayerova; Fiscal Year: 2003
    ..Further, we propose to identify G proteins and downstream effectors activated by beta-chemokine binding to CCR5 receptors expressed in macrophages, and to characterize their effects on the signaling pathways involved in HIV-1 ..
  24. MENTORING IN MOUSE MOLECULAR PATHOBIOLOGY RESEARCH
    David Huso; Fiscal Year: 2005
    ....
  25. HIV IMMUNE RESPONSE IN RWANDAN RAPID AND NON-PROGRESSORS
    Pauline Jolly; Fiscal Year: 2000
    ..They will measure CCR5 receptor expression and determine the relationship between b-chemokine production, CCR5 expression, and polymorphisms in the CCR5 promoter. ..
  26. MIP-1B Structural Features Responsible for Function
    Patricia LiWang; Fiscal Year: 2005
    ..These three Specific Aims will delineate the molecular details of MIP-1beta binding to its biological partners, and will allow the design of specific, tight-binding anti-HIV therapeutics. ..
  27. HIV-1 Fusion Coreceptors
    Christopher Broder; Fiscal Year: 2003
    ..approaches in conjunction with the use and characterization of a battery of non-human primate CD4 and CCR5 receptors; employ our assays of tri-molecular complex formation and analysis; and our assays for measuring fusion and ..
  28. HIV NEUTRALIZATION IN VITRO & IN SHIV-INFECTED MACAQUES
    John Moore; Fiscal Year: 2001
    ....
  29. CHRYSTALLIZING DISULFIDE-STABILIZED HIV-1 ENV PROTEINS
    John Moore; Fiscal Year: 2004
    ..Any information accruing from the structure of a native Env trimer could facilitate the rational design of Env-based vaccines. ..
  30. ENTRY INHIBITORS AS TOPICAL MICROBICIDES AGAINST HIV-1
    John Moore; Fiscal Year: 2004
    ..Moore, Ph.D., Fusion-Inhibitor Acquisition, Evaluation and Formulation; Administrative Core: John P. Moore, Ph.D. ..
  31. Modified Envelope Glycoproteins for HIV-1 Vaccine
    John P Moore; Fiscal Year: 2010
    ..11/07) Page 2 Form Page 2 ..
  32. Role of CCL2/MCP-1 in mucosal immunity to Toxoplasma
    ERIC DENKERS; Fiscal Year: 2008
    ..This project will enhance our understanding of immunity to the parasite, leading to improved treatment strategies. [unreadable] [unreadable] [unreadable]..
  33. ROLE OF NEUTROPHILS DURING TOXOPLASMOSIS
    ERIC DENKERS; Fiscal Year: 2008
    ..Understanding how immunity is triggered can be expected to lead to more effective means of controlling infection with Toxoplasma and other microbial pathogens. ..
  34. Immunobiology of Parasitic Diseases
    ERIC DENKERS; Fiscal Year: 2005
    ..Existing support for the program is substantial in the form of research environment and facilities, the Cornell Biotechnology Program and computing and library systems ..
  35. CONFERENCE ON HIV PATHOGENESIS
    Michael Lederman; Fiscal Year: 2005
    ....
  36. Cross-reactive HERV immunity to combat HIV-1 infection
    Donald E Mosier; Fiscal Year: 2010
    ..The result will be "cross-protective" immunity, as best exemplified by the eradication of smallpox by vaccination with the related cowpox virus. ..
  37. The Transmission and Fitness of Drug Resistant HIV-1
    MARTIN H MARKOWITZ; Fiscal Year: 2011
    ..abstract_text> ..
  38. Migration of Mature and Immature Dendritic Cells
    HENDRIK VAN DEVENTER; Fiscal Year: 2006
    ..All have extensive experience in developing the careers o f young scientists. This work has the support of the Lineberger Comprehensive Cancer Center which has made accessible its core facilities. ..
  39. Immunogenicity of an HIV virus-like particle vaccine
    Feng Gao; Fiscal Year: 2004
    ..abstract_text> ..
  40. Mechanism of HIV-1 inhibition by alpha-defensin-1
    Theresa Chang; Fiscal Year: 2005
    ..abstract_text> ..
  41. A Universal Env Immunogen for all HIV-1 Subtypes
    Feng Gao; Fiscal Year: 2004
    ..Results from this study will determine if con/con Env protein can serve as a universal immunogen for all HIV-1 subtypes and will be used as a guideline to design broadly reactive immunization strategies. ..
  42. CHEMOKINE RECEPTORS IN IMMUNITY TO C NEOFORMANS
    GARY HUFFNAGLE; Fiscal Year: 2003
    ..neoformans infection; (5) To determine the role of MCP-1 and CCR2 in the development of a Th2 response to C. neoformans. ..
  43. Understanding and Altering the Virologic Setpoint
    Martin Markowitz; Fiscal Year: 2006
    ..abstract_text> ..
  44. HIV CORECEPTOR SWITCHING
    Donald E Mosier; Fiscal Year: 2010
    ..These experiments are highly relevant to the approaching use of CCR5 inhibitors in phase III clinical trials, and may well predict the probability of resistance to this class of antivirals. ..
  45. NeuroAIDS in Cameroon: Molecular determinants
    GEORGETTE KANMOGNE; Fiscal Year: 2008
    ..It will provide knowledge on the epidemiology of neuroAIDS in Cameroon and build the capacity for future neuroAIDS research and therapeutic testing in Cameroon. [unreadable] [unreadable] [unreadable]..
  46. MODULATION OF TH1/TH2 RESPONSES BY INNATE IMMUNITY
    GARY HUFFNAGLE; Fiscal Year: 2004
    ..One of the potential implications of these studies is that therapies inhibiting melanin biosynthesis or activity may also have an adjuvant effect and promote the development of protective Th1 immunity to C. neoformans. ..
  47. HIV-1 gp120-induced Endothelial Cell Dysfunction
    GEORGETTE KANMOGNE; Fiscal Year: 2007
    ....
  48. Immune Mechanisms and HIV Disease Pathogenesis
    Michael Lederman; Fiscal Year: 2004
    ..The proposal's specific request is for support to increase participation in the Conference by female and/or minority researchers and students. ..
  49. Chemokine Receptor Signaling in HIV Neuropathology
    Marcus Kaul; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  50. Case CFAR Meeting: HIV Pathogenesis
    Michael Lederman; Fiscal Year: 2006
    ..Presentation sessions will be Cellular Restrictions Factors; Latency; Protection from HIV Infection; Immune Pathogenesis; and Vaccines. ..
  51. Topical Immune modulatory strategies to prevent HIV transmission
    Michael Lederman; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  52. Recombinant CCR5 Inhibitors for Topical Microbicides
    Donald Mosier; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  53. 2007 Case CFAR Annual Spring Conference
    Michael Lederman; Fiscal Year: 2007
    ..The Case CFAR is proactive in its efforts to ensure inclusion of minority and female researchers in[unreadable] all aspects of Conference planning and attendance. ..
  54. Role of Oxylipins in Cryptococcal Pathogenesis
    GARY HUFFNAGLE; Fiscal Year: 2008
    ..production; (3) to determine the role of the fungal oxylipin CnPGEx in cryptococcal biology and pathogenesis; (4) to determine the role of host PGE2 and other prostaglandins in cryptococcal biology and host immunity ..
  55. Role of Virus Recombination in Multiple Drug Resisitance
    Feng Gao; Fiscal Year: 2007
    ..Knowledge obtained from this study can be broadly applied toward understanding mechanisms of viral escape from immune surveillance and other selective forces. ..
  56. Defensins in STI-mediated enhancement of HIV Infection
    Theresa Chang; Fiscal Year: 2008
    ..A longer term outcome could be the development of novel prevention strategies. [unreadable] [unreadable] [unreadable] [unreadable]..
  57. Role of Fungal Microflora in Mucosal Tolerance/Immunity
    GARY HUFFNAGLE; Fiscal Year: 2009
    ..These studies will provide the basic science foundation for future studies in humans for understanding how and why manipulation of the microflora (by diet or probiotics) can alter or prevent allergies. ..
  58. CORECEPTORS AND VIRAL TROPISM IN HIV-1 NEUROPATHOGENESIS
    MARK GOLDSMITH; Fiscal Year: 2001
    ..abstract_text> ..
  59. Novel Animal Model System of AIDS-Kaposi Sarcoma
    Patricio Ray; Fiscal Year: 2005
    ....
  60. Structure/Functional Characterization of vWF-A1 Domain
    THOMAS DIACOVO; Fiscal Year: 2007
    ..Information from these studies may aid in the design of antithrombotics with specific kinetic properties that can compete with the native-ligand pair. ..
  61. CD28/B7 Costimulation Blockade-Resistant Graft Rejection
    Wayne Hancock; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  62. Immunobiology and Prevention of H. pylori Disease
    Phillip Smith; Fiscal Year: 2009
    ..pylori urease plus IL-10 or FoxP3 (the Tr cell transcription factor) protects mice against H. pylori infection. ..